US Fund Platinum in Talks to Acquire Inventia Health

According to multiple people who are aware of the development, the contract drugmaker Inventia Healthcare, which is based in Mumbai, is being considered for acquisition by the US buyout fund Platinum Equity Advisors at a valuation of 2,500 crore (300 million dollars).

Existing investors InvAscent Capital and Jacob Ballas that together hold 40% stake in Inventia are set to exit their investments while promoter Janak Shah and family, which own the rest of the stake, will retain a minority stake and manage the business, as per economic times.

"The existing private equity funds are evaluating an exit and hence, there is a process being run to facilitate their exit," Ankur Shah, director at Inventia Healthcare, said. "The process is now at a diligence stage with a number of potential parties involved in the diligence process including private equity funds," he added without naming any company. Post the transaction, the promoter family intends to be in charge and continue to lead the company, Shah said.

The sale of Inventia is being managed by Rothschild & Co. and the healthcare-focused investment bank Stifel Financial Corp. (Torreya), as well as a few large private equity funds.

Established in 1995, Platinum Value is a worldwide trading company with roughly $47 billion of resources under administration and an arrangement of 50 working organizations. As of late, Platinum had employed Amit Sobti as head of Asia to grow its presence in business sectors like India. Once appeared, Inventia buyout would be their presentation private value bargain in India.

Inventia, a contract manufacturing company that was established in 1985, creates oral dosage formulations with value added for a variety of Indian and international pharmaceutical companies.